Anke Biotechnology's Investee Company Receives Approval for New Indication Clinical Trial of PA3-17 Injection

People's Finance News, March 4thANKEBIO(300009) Announcement on March 4, ANKEBIO's participating companies, Bo sheng ji medicine science and technology (suzhou) co., LTD and Bo sheng ji Anke Cell Technology Co., Ltd, received the "Drug Clinical Trial Approval Notice" issued by the National Medical Products Administration. The clinical trial application for a new indication of their self-developed PA3-17 injection has been approved by the National Medical Products Administration, agreeing to conduct clinical trials for the treatment of children and adolescents with relapsed/refractory T lymphoblastic leukemia/lymphoma.